In addition, MUC1 was reported to be useful in predicting prognosis in NSCLC patients (Zhu et al., 2014) and may contribute to the treatment of patients with NSCLC resistant to EGFR kinase inhibitors (Kharbanda et al., 2014), indicating that our identified functional epigenetic module MUC1 may play an important role in the development and prognosis of LUAD. Here, MUC1 is linked to non-small cell lung carcinoma.